Traitement de la sclérodermie systémique

LeRoy, 1988, Scleroderma (systemic sclerosis): classification, subsets and pathogenesis, J Rheumatol, 15, 202 Valentini, 2003, The assessment of the patient with systemic sclerosis, Clin Exp Rheum, 21, S2 Ioannidis, 2005, Mortality in systemic sclerosis: an international meta-analysis of individual patient data, Am J Med, 118, 2, 10.1016/j.amjmed.2004.04.031 Scussel-Lonzetti, 2002, Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival, Medicine (Baltimore), 81, 154, 10.1097/00005792-200203000-00005 Ferri, 2002, Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSScS). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients., Medicine (Baltimore), 81, 139, 10.1097/00005792-200203000-00004 Steen, 2003, Scleroderma renal crisis, Rheum Dis Clin North Am, 29, 315, 10.1016/S0889-857X(03)00016-4 DeMarco, 2002, Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial, Arthritis Rheum, 46, 2983, 10.1002/art.10589 Mukerjee, 2003, Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach, Ann Rheum Dis, 62, 1088, 10.1136/ard.62.11.1088 Allanore, 2003, N-terminal pro-brain natriuretic peptide as a diagnostic marker ofearly pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers, Arthritis Rheum, 48, 3503, 10.1002/art.11345 Steen, 2003, Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement, Arthritis Rheum, 48, 516, 10.1002/art.10775 Kuhn, 2003, Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol, Am J Respir Crit Care Med, 167, 580, 10.1164/rccm.200204-333OC Badesch, 2000, Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial, Ann Intern Med, 132, 425, 10.7326/0003-4819-132-6-200003210-00002 Olschewski, 2002, Inhaled iloprost for severe pulmonary hypertension, N Engl J Med, 347, 322, 10.1056/NEJMoa020204 Rubin, 2002, Bosentan therapy for pulmonary arterial hypertension, N Engl J Med, 346, 896, 10.1056/NEJMoa012212 McLaughlin, 2005, Survival with first-line bosentan in patients with primary pulmonary hypertension, Eur Respir J, 25, 244, 10.1183/09031936.05.00054804 Barst, 2004, Sitaxsentan therapy for pulmonary arterial hypertension, Am J Respir Crit Care Med, 169, 441, 10.1164/rccm.200307-957OC Wilkins, 2005, Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study, Am J Respir Crit Care Med, 171, 1292, 10.1164/rccm.200410-1411OC White, 2000, Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis, Ann Intern Med, 132, 947, 10.7326/0003-4819-132-12-200006200-00004 Airo, 2004, Intravenous cyclophosphamide therapy for systemic sclerosis A single-center experience and review of the literature with pooled analysis of lung function test results, Clin Exp Rheumatol, 22, 573 Clements, 1991, Cardiacscore. A semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis, Arthritis Rheum, 34, 1371, 10.1002/art.1780341105 Kahan, 1986, Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis, N Engl J Med, 314, 1397, 10.1056/NEJM198605293142201 Meune, 2004, High prevalence of right ventricular systolic dysfunction in early systemic sclerosis, J Rheumatol, 31, 1941 Vignaux, 2005, Evaluation of nifedipine efficacy up on myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis, Ann Rheum Dis, 64, 1268, 10.1136/ard.2004.031484 Kahan, 1990, The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis, Clin Pharmacol Ther, 47, 483, 10.1038/clpt.1990.61 Thompson, 2005, Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis, Rheumatology (Oxford), 44, 145, 10.1093/rheumatology/keh390 Allanore, 2004, Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis, Am J Med, 116, 595, 10.1016/j.amjmed.2003.11.022 Allanore, 2005, Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis, Arthritis Res Ther, 7, R93, 10.1186/ar1457 Herrick, 2001, The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis, Clin Exp Rheumatol, 19, 4 Korn, 2004, Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist, Arthritis Rheum, 50, 3985, 10.1002/art.20676 Rajagopalan, 2003, Effects of cilostazol in patients with Raynaud's syndrome, Am J Cardiol, 92, 1310, 10.1016/j.amjcard.2003.08.013 Wise, 2004, Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study, Arthritis Rheum, 50, 3994, 10.1002/art.20665 Kotsis, 2003, A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia, J Rheumatol, 30, 1788 Scorza, 2001, Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study, Clin Exp Rheumatol, 19, 503 Steen, 2001, Improvement in skin thickening in systemic sclerosis associated with improved survival, Arthritis Rheum, 44, 2828, 10.1002/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U Clements, 1999, High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial, Arthritis Rheum, 42, 1194, 10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7 Pope, 2001, A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma, Arthritis Rheum, 44, 1351, 10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I Seibold, 2000, Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 132, 871, 10.7326/0003-4819-132-11-200006060-00004 Mayes, 2004, Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial, Arthritis Rheum., 50, 553, 10.1002/art.20036 Farge, 2004, Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry, Ann Rheum Dis, 63, 974, 10.1136/ard.2003.011205 Kahan, 1989, Recombinant interferon-gamma in the treatment of systemic sclerosis, Am J Med, 87, 273, 10.1016/S0002-9343(89)80150-0 Grassegger, 1998, Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial, Br J Dermatol, 139, 639, 10.1046/j.1365-2133.1998.02460.x Black, 1999, Interferon-alpha doest not improve outcome at one year in patients with diffuse scleroderma: results from a randomized double-blind, placebo-controled trial, Arthritis Rheum, 42, 299, 10.1002/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R Denton, 2004, Anti-TGFβ1 therapy for diffuse cutaneous systemic sclerosis: a multicenter, randomized, placebo-controlled Phase I/II Trial. of CAT-192, Arthritis Rheum, 50